Vanguard Personalized Indexing Management
CYTK icon

Vanguard Personalized Indexing Management’s Cytokinetics CYTK Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
26,340
+2,505
+11% +$180K 0.02% 602
2026
Q1 		$1.57M Buy
23,835
+3,110
+15% +$198K 0.02% 712
2025
Q4 		$1.32M Buy
20,725
+2,641
+15% +$164K 0.01% 789
2025
Q3 		$994K Buy
18,084
+4,493
+33% +$185K 0.01% 905
2025
Q2 		$449K Buy
13,591
+1,509
+12% +$52.5K 0.01% 1245
2025
Q1 		$486K Buy
12,082
+5,096
+73% +$234K 0.01% 1133
2024
Q4 		$329K Buy
6,986
+305
+5% +$15.8K 0.01% 1298
2024
Q3 		$353K Sell
6,681
-1,363
-17% -$76K 0.01% 1268
2024
Q2 		$436K Sell
8,044
-638
-7% -$38.5K 0.01% 1096
2024
Q1 		$609K Buy
8,682
+3,193
+58% +$247K 0.01% 907
2023
Q4 		$458K Buy
+5,489
New +$199K 0.01% 1043

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's CYTK Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Cytokinetics (CYTK) stake by 11% in Q2 2026, buying an estimated $180K and bringing the position to 26,340 shares worth $2.24M. The position accounts for 0.02% of the portfolio, ranked #602.

Vanguard Personalized Indexing Management first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Personalized Indexing Management held 26,340 shares of Cytokinetics worth $2.24M as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 2,505 Cytokinetics shares in Q2 2026, an estimated $180K.
  • Cytokinetics made up 0.02% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #602 holding.
  • Vanguard Personalized Indexing Management first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.